Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

CBLL - CeriBell, Inc. Последние новости | Finranks

Home

CBLL

(CBLL)

NMS – Цена в реальном времени. Валюта: USD

17.77

-0.63 (-3.42%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

17.77

0.00 (0.00%)

После закрытия: Mar 27, 2026, 4:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights

AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.

CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript

CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates

CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.

Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Ceribell to Participate in Upcoming March Investor Conferences

Ceribell to Participate in Upcoming March Investor Conferences

SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m. Eastern Standard Time. Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:50 a.m. Pacific Standard Time / 1:50 p.m. Eastern Standard Time.

Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026.

CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Видео

No Data

There is no data to display

Пресс-релизы

Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for patients in the hospital setting.

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution

SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium screening and monitoring device.